Can-Fite Phase 2-3 Psoriasis Study

Can-Fite BioPharma is continuing patient enrollment in its Psoriasis Phase 2/3 clinical study with CF101. This decision follows an interim analysis of safety and efficacy data from the first 103 patients who completed 24 weeks of treatment in the trial. The positive clinical effects of the CF101-2 mg BID dose relative to placebo were observed in a variety of standard psoriasis assessment parameters, with the responses accumulating steadily over the 24-week treatment period. These clinical effect data corroborate the published Phase 2 study and confirm the dose selection, while the favorable safety profile of CF101 further supports its development for the systemic treatment of moderate-to-severe psoriasis. To allow the trial to meet its full objectives, the company therefore intends to complete patient enrollment for this Psoriasis Phase 2/3 clinical study comparing CF101-2 mg BID to placebo, as standalone therapy. The study will include approximately 300 patients overall and is currently conducted in 17 U.S., European and Israeli medical centers.

Written by

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam libero diam, elementum eget porttitor at, tincidunt at nulla.